About Recombinetics
Recombinetics is a company based in Eagan (United States) founded in 2008. Recombinetics has raised $65.54 million across 23 funding rounds from investors including NIH, HHS and National Cancer Institute. The company has 29 employees as of December 31, 2022. Recombinetics offers products and services including Gene Edited Swine Models and Precision Breeding Services. Recombinetics operates in a competitive market with competitors including Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
- Headquarter Eagan, United States
- Employees 29 as on 31 Dec, 2022
-
Sectors
HealthcareAgriculture
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$65.54 M (USD)
in 23 rounds
-
Latest Funding Round
$385 K (USD), Grant
Jun 01, 2024
-
Investors
NIH
& 2 more
-
Employee Count
29
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Recombinetics
Recombinetics offers a comprehensive portfolio of products and services, including Gene Edited Swine Models and Precision Breeding Services.
Custom models for preclinical research to advance healthcare innovations.
Breeding methods to improve animal health and sustainable farming practices.
People of Recombinetics
Unlock access to complete
Unlock access to complete
Funding Insights of Recombinetics
Recombinetics has successfully raised a total of $65.54M across 23 strategic funding rounds. The most recent funding activity was a Grant round of $385 thousand completed in June 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Recombinetics
Recombinetics has secured backing from 3 investors, including institutional investors. Prominent investors backing the company include NIH, HHS and National Cancer Institute.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Cancer research is conducted and supported by the institute.
|
Locked | Locked | Locked | |
|
Public health and human services are overseen by HHS.
|
Locked | Locked | Locked | |
|
Drug discovery services are provided to the biopharma sector.
|
Locked | Locked | Locked |
Investor details for Recombinetics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Recombinetics
Investment portfolio details for Recombinetics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Recombinetics
Detailed financials for Recombinetics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Recombinetics Comparisons
Peer comparison for Recombinetics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Recombinetics
Recombinetics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Avidity Biosciences, Univercells, Sutro Biopharma, Vividion Therapeutics and Straumann Group, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody-siRNA complexes are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biomanufacturing technologies are supplied for biopharma antibody and vaccine production.
|
|
| Locked | Locked | Locked |
Antibody-based therapeutics for cancer therapy are developed via cell-free synthesis.
|
|
| Locked | Locked | Locked |
Developing novel drugs based on a proteome-wide ligand and target discovery platform
|
|
| Locked | Locked | Locked |
Dental implants and regenerative dentistry products are developed.
|
|
| Locked | Locked | Locked |
RNA-editing technologies are provided for precision medicine applications.
|
Detailed competitors of Recombinetics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Recombinetics
Complete news archive for Recombinetics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Recombinetics
Recombinetics was founded in 2008 and raised its 1st funding round 3 years after it was founded.
Recombinetics is headquartered in Eagan, United States. It is registered at Eagan, Minnesota, United States.
Recombinetics is a funded company, having raised a total of $65.54M across 23 funding rounds to date.
As of Dec 31, 2022, the latest employee count at Recombinetics is 29.
Recombinetics was founded in 2008 and is headquartered in Eagan, United States. Operations focus on the biotechnology sector, where proprietary gene repair and editing tools, including TALEN technologies, are applied. In agriculture, these are used to introduce natural traits into pigs and other livestock, aiming to improve health, welfare, and food safety. In biomedicine, large animal models for human disease research are created to support therapeutic and device development.
Recombinetics's top competitors include Sutro Biopharma, Synthego and Avidity Biosciences.
Recombinetics offers Gene Edited Swine Models and Precision Breeding Services.
Recombinetics has 3 investors. Key investors include NIH, HHS, and National Cancer Institute.